ZFIN ID: ZDB-PUB-170914-2
A multiplex preclinical model for adenoid cystic carcinoma of the salivary gland identifies regorafenib as a potential therapeutic drug
Chen, C., Choudhury, S., Wangsa, D., Lescott, C.J., Wilkins, D.J., Sripadhan, P., Liu, X., Wangsa, D., Ried, T., Moskaluk, C., Wick, M.J., Glasgow, E., Schlegel, R., Agarwal, S.
Date: 2017
Source: Scientific Reports   7: 11410 (Journal)
Registered Authors: Glasgow, Eric
Keywords: Cancer, Oncology
MeSH Terms:
  • Animals
  • Antineoplastic Agents/pharmacology*
  • Biomarkers, Tumor
  • Carcinoma, Adenoid Cystic/drug therapy*
  • Carcinoma, Adenoid Cystic/genetics
  • Carcinoma, Adenoid Cystic/pathology
  • Cell Line, Tumor
  • Cell Transformation, Neoplastic/genetics
  • Cell Transformation, Neoplastic/metabolism
  • Disease Models, Animal
  • Drug Evaluation, Preclinical
  • Gene Expression Profiling
  • Gene Expression Regulation, Neoplastic
  • Humans
  • In Situ Hybridization, Fluorescence
  • Mice
  • Microsatellite Repeats
  • Oncogene Proteins, Fusion/genetics
  • Oncogene Proteins, Fusion/metabolism
  • Phenylurea Compounds/pharmacology*
  • Pyridines/pharmacology*
  • Salivary Gland Neoplasms/drug therapy*
  • Salivary Gland Neoplasms/genetics
  • Salivary Gland Neoplasms/pathology
  • Xenograft Model Antitumor Assays
  • Zebrafish
PubMed: 28900283 Full text @ Sci. Rep.
Adenoid cystic carcinomas (ACC) are rare salivary gland cancers with a high incidence of metastases. In order to study this tumor type, a reliable model system exhibiting the molecular features of this tumor is critical, but none exists, thereby inhibiting in-vitro studies and the analysis of metastatic behavior. To address this deficiency, we have coupled an efficient method to establish tumor cell cultures, conditional reprogramming (CR), with a rapid, reproducible and robust in-vivo zebrafish model. We have established cell cultures from two individual ACC PDX tumors that maintain the characteristic MYB translocation. Additional mutations found in one ACC culture also seen in the PDX tumor. Finally, the CR/zebrafish model mirrors the PDX mouse model and identifies regorafenib as a potential therapeutic drug to treat this cancer type that mimic the drug sensitivity profile in PDX model, further confirming the unique advantages of multiplex system.